ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.
Abstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The clinical characteristics and treatment of ovarian malignant mesoderm mixed tumor: a systematic review.Journal of ovarian research · 2022Pooled it
- Advances and Future Directions in Antibody-Drug Conjugates: From Paradigm Shifts to Data-Driven Design.Cancers · 2026Review
- Seco-Duocarmycin SA in Aggressive Glioblastoma Cell Lines.International journal of molecular sciences · 2025Article
- HER2-negative or low expression as an unfavorable prognostic factor in patients with stage I/II uterine carcinosarcoma.Journal of gynecologic oncology · 2025Article
- Advancements in research and clinical management of interstitial lung injury associated with ADC drugs administration in breast cancer.Discover oncology · 2024Review
- Unveiling the future of breast cancer therapy: Cutting-edge antibody-drug conjugate strategies and clinical outcomes.Breast (Edinburgh, Scotland) · 2024Review
- Article
- Duocarmycin SA Reduces Proliferation and Increases Apoptosis in Acute Myeloid Leukemia Cells In Vitro.International journal of molecular sciences · 2024Article
- Mesothelin expression in gynecologic carcinosarcoma: clinicopathological significance and correlation with HER2 expression.Journal of gynecologic oncology · 2024Article
- HER2-targeted therapies in cancer: a systematic review.Biomarker research · 2024Review
- Clinicopathological and molecular features of tubo-ovarian carcinosarcomas: a series of 51 cases.Frontiers in oncology · 2024Article
- Antibody-Drug Conjugates (ADC) in HER2/neu-Positive Gynecologic Tumors.Molecules (Basel, Switzerland) · 2023Review
- The History and Development of HER2 Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2023Review
- HER2 Oncogene as Molecular Target in Uterine Serous Carcinoma and Uterine Carcinosarcoma.Cancers · 2023Review
- Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody-drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression.Gynecologic oncology · 2023Article
- Breast cancer heterogeneity and its implication in personalized precision therapy.Experimental hematology & oncology · 2023Review
- Value of Antibody Drug Conjugates for Gynecological Cancers: A Modern Appraisal Following Recent FDA Approvals.International journal of women's health · 2023Review
- Beyond Serous: Treatment Options for Rare Endometrial Cancers.Current treatment options in oncology · 2022Review
- Biosynthesis of DNA-Alkylating Antitumor Natural Products.Molecules (Basel, Switzerland) · 2022Review
- Management of a rare ovarian carcinosarcoma: A case report and literature review.Experimental and therapeutic medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Gulden MenderesDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Elena BonazzoliDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Stefania BelloneDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Jonathan BlackDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Federica PredoliniDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Francesca PettinellaDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Alice MasserdottiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Luca ZammataroDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Gary AltwergerDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Natalia BuzaDepartment of Pathology, Yale University School of Medicine, Connecticut.
Pei HuiDepartment of Pathology, Yale University School of Medicine, Connecticut.
Serena WongDepartment of Pathology, Yale University School of Medicine, Connecticut.
Babak LitkouhiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Elena RatnerDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Dan-Arin SilasiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Masoud AzodiDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Peter E SchwartzDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut.
Alessandro D SantinDepartment of Obstetrics, Gynecology and Reproductive Sciences, Yale University School of Medicine, Connecticut. alessandro.santin@yale.edu.
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0MIntegrated genomic analysis of racial disparities in endometrial cancerU01CA176067 · NCI · YALE UNIVERSITY · PI SANTIN, ALESSANDRO D · 2014 to 2018
$1.7MCPE Peptide-Based Nanoparticles for the Diagnosis and Therapy of Chemotherapy ResR01CA154460 · NCI · YALE UNIVERSITY · PI SANTIN, ALESSANDRO D · 2011 to 2015
$1.7MNCATS NIH HHS UL1 TR001863NCI NIH HHS P30 CA016359NCI NIH HHS R01 CA154460NCI NIH HHS U01 CA176067
Abstract
PubMed holds no abstract for this paper.
Indexed as
Ado-Trastuzumab EmtansineAnimalsAntibody-Dependent Cell CytotoxicityCarcinosarcomaCell Line, TumorCell ProliferationDuocarmycinsErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansImmunoconjugatesIndolesMaytansineMiceOvarian NeoplasmsAdo-Trastuzumab Emtansineduocarmycin ADuocarmycinsERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesImmunoconjugatesIndolesMaytansinePyrrolidinonesTrastuzumab
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.